Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Payables (2020 - 2025)

Maxcyte (MXCT) has disclosed Payables for 6 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 31.05% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 31.05% decrease, with the full-year FY2024 number at $1.4 million, up 82.77% from a year prior.
  • Payables was $1.3 million for Q3 2025 at Maxcyte, up from $1.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $4.4 million in Q1 2022 to a low of $292000.0 in Q4 2022.
  • A 5-year average of $1.6 million and a median of $1.5 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 83.96% in 2022, then soared 317.6% in 2024.
  • Maxcyte's Payables stood at $1.8 million in 2021, then plummeted by 83.96% to $292000.0 in 2022, then skyrocketed by 154.45% to $743000.0 in 2023, then skyrocketed by 82.77% to $1.4 million in 2024, then fell by 5.3% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Payables are $1.3 million (Q3 2025), $1.2 million (Q2 2025), and $2.3 million (Q1 2025).